Cohance Lifesciences Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
2,811
- Stock Symbol
-
543064
- Investments
-
7
- Share Price
-
$4.95
- (As of Friday Closing)
Cohance Lifesciences General Information
Description
Cohance Lifesciences Ltd is a science-led CRDMO and life sciences company providing contract research, development, and manufacturing services to pharmaceutical, biotechnology, and specialty chemical customers. The company operates as a single reporting segment focused on CDMO services, supported by capabilities in APIs, formulations, antibody-drug conjugates (ADCs), oligonucleotides, and specialty chemicals. It serves customers through an integrated network of manufacturing and R&D facilities across India and the United States, offering end-to-end solutions from development to commercial manufacturing. Geographically, it operates in Europe, USA, India and Rest of the world.
Contact Information
Website
www.cohance.comCorporate Office
- 202, A-Wing, Galaxy Towers, Plot Number 1, Hyderabad Knowledge City, TSIIC
- Raidurg, Serilingampally, Rangareddy District
- Hyderabad, Telangana 500081
- India
Corporate Office
- 202, A-Wing, Galaxy Towers, Plot Number 1, Hyderabad Knowledge City, TSIIC
- Raidurg, Serilingampally, Rangareddy District
- Hyderabad, Telangana 500081
- India
Cohance Lifesciences Stock Performance
As of 20-Nov-2026, Cohance Lifesciences’s stock price is $4.95. Its current market cap is $1.89B with 383M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.95 | $4.91 | $2.91 - $6.78 | $1.89B | 383M | 135K | $0.01 |
Cohance Lifesciences Financials Summary
As of 30-Sep-2026, Cohance Lifesciences has a trailing 12-month revenue of $222M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,790,491 | 1,238,048 | 3,377,195 | 1,986,531 |
| Revenue | 222,455 | 249,402 | 298,759 | 124,908 |
| EBITDA | 25,472 | 48,242 | 99,974 | 56,204 |
| Net Income | 5,109 | 20,283 | 57,634 | 36,272 |
| Total Assets | 591,370 | 607,258 | 640,753 | 270,394 |
| Total Debt | 46,684 | 42,446 | 56,808 | 7,796 |
Cohance Lifesciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cohance Lifesciences Comparisons
Industry
Financing
Details
Cohance Lifesciences Competitors (5)
One of Cohance Lifesciences’s 5 competitors is Evotec, a Formerly PE-Backed company based in Hamburg, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evotec | Formerly PE-Backed | Hamburg, Germany | ||||
| Syngene International | Formerly PE-Backed | Bangalore, India | ||||
| Suven Life Sciences | Corporation | Hyderabad, India | ||||
| Sai Life Sciences | Formerly VC-backed | Hyderabad, India | ||||
| Divi's Laboratories | Corporation | Hyderabad, India |
Cohance Lifesciences Signals
Cohance Lifesciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cohance Lifesciences Investments & Acquisitions (7)
Cohance Lifesciences’s most recent deal was a Later Stage VC with NJ Bio for . The deal was made on 12-Aug-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NJ Bio | 12-Aug-2025 | Later Stage VC | Other Pharmaceuticals and Biotechnology | ||
| NJ Bio | 20-Dec-2024 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Sapala | 12-Jul-2024 | Merger/Acquisition | Multi-line Chemicals | ||
| RA Chem Pharma | 01-Nov-2022 | Buyout/LBO | Other Pharmaceuticals and Biotechnology | ||
| Casper Pharma | 05-Apr-2022 | Merger/Acquisition | Pharmaceuticals |
Cohance Lifesciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
17.22 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Cohance Lifesciences Exits (1)
Cohance Lifesciences’s most recent exit was on 07-Mar-2019 from Rising Pharma Holdings. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Rising Pharma Holdings | 07-Mar-2019 | Completed |
|
Cohance Lifesciences Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NJ Bio | Princeton, NJ | 2018 | |
| Casper Pharma | East Brunswick, NJ | 2016 | |
| Sapala | Hyderabad, India | 2005 |
Cohance Lifesciences FAQs
-
When was Cohance Lifesciences founded?
Cohance Lifesciences was founded in 2018.
-
Where is Cohance Lifesciences headquartered?
Cohance Lifesciences is headquartered in Hyderabad, India.
-
What is the size of Cohance Lifesciences?
Cohance Lifesciences has 2,811 total employees.
-
What industry is Cohance Lifesciences in?
Cohance Lifesciences’s primary industry is Pharmaceuticals.
-
Is Cohance Lifesciences a private or public company?
Cohance Lifesciences is a Public company.
-
What is Cohance Lifesciences’s stock symbol?
The ticker symbol for Cohance Lifesciences is 543064.
-
What is the current stock price of Cohance Lifesciences?
As of 20-Nov-2026 the stock price of Cohance Lifesciences is $4.95.
-
What is the current market cap of Cohance Lifesciences?
The current market capitalization of Cohance Lifesciences is $1.89B.
-
What is Cohance Lifesciences’s current revenue?
The trailing twelve month revenue for Cohance Lifesciences is $222M.
-
Who are Cohance Lifesciences’s competitors?
Evotec, Syngene International, Suven Life Sciences, Sai Life Sciences, and Divi's Laboratories are competitors of Cohance Lifesciences.
-
What is Cohance Lifesciences’s annual earnings per share (EPS)?
Cohance Lifesciences’s EPS for 12 months was $0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process